BioSpace News Archive

Hoth Therapeutics, Inc., a patient focused clinical stage biopharmaceutical company, announced the closing of its previously announced private placement of common stock and warrants to purchase shares of common stock priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $15.0 million.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter and full year ended December 31, 2020.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced that it has completed the previously announced transaction with Topcon Corporation.

Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track

Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that it has been invited to participate in the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021.

Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, provided a business update and financial results for the year ended December 31, 2020.